Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients

Imatinib is the most common first-line tyrosine kinase inhibitor (TKI) used to treat chronic-phase chronic myeloid leukemia (CP-CML). However, only a proportion of patients achieve major molecular response (MMR), so there is a need to find biological factors that aid the selection of the optimal the...

Descripción completa

Detalles Bibliográficos
Autores principales: Estrada, Natalia, Zamora, Lurdes, Ferrer-Marín, Francisca, Palomo, Laura, García, Olga, Vélez, Patricia, De la Fuente, Iris, Sagüés, Miguel, Cabezón, Marta, Cortés, Montserrat, Vallansot, Rolando Omar, Senín-Magán, María Alicia, Boqué, Concepción, Xicoy, Blanca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604607/
https://www.ncbi.nlm.nih.gov/pubmed/36294538
http://dx.doi.org/10.3390/jcm11206217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604607/
https://www.ncbi.nlm.nih.gov/pubmed/36294538
http://dx.doi.org/10.3390/jcm11206217

Ejemplares similares